Clinical Trials Browser

Active not recruiting × Parkinson Disease 4, Autosomal Dominant Lewy Body × Genitourinary × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT04626479 2026-02-12

MK-3475-03A

Phase 1/2 Active not recruiting

400 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05899049 2025-11-10

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Phase 3 Active not recruiting

249 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT06307431 2025-09-02

INTerpath-004

Phase 2 Active not recruiting

272 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03924856 2025-08-28

KEYNOTE-866

Phase 3 Active not recruiting

907 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT05239728 2025-08-14

MK-6482-022

Phase 3 Active not recruiting

1,800 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04626518 2025-07-25

KEYMAKER-U03

Phase 1/2 Active not recruiting

370 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03834493 2025-07-18

KEYNOTE-641

Phase 3 Active not recruiting

1,244 enrolled 21 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT04736706 2024-11-18

MK-6482-012

Phase 3 Active not recruiting

1,653 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

Clinical Trials

MK-3475-04C

MK-3475-03A

INTerpath-004

KEYNOTE-866

MK-6482-022

KEYMAKER-U03

KEYNOTE-641

MK-6482-012